Skip to content

Royalty Pharma

US · RPRX #759 by market cap Listed 2020
68.45 +0.73 +1.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.5 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
87.61% -0.46pp
Institutions
902 -4
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund74.51%
Individual/Insider6.11%
Hedge Fund4.73%
Public Company2.55%
Private Company2.03%
Government Pension Fund1.53%
Sovereign Wealth Fund1.28%
Family Office/Trust0.27%
Endowment Fund0.23%
Insurance Company0.21%
Other6.76%

Top holders as of 2026-09-30

Capital Research 10.21% · 45.48M sh
Morgan Stanley Investment Management Inc. 8.03% · 35.74M sh
BlackRock 6.54% · 29.12M sh
Mario Giuliani 4.80% · 21.37M sh
T. Rowe Price Group, Inc. 3.30% · 14.71M sh
FMR 3.20% · 14.26M sh
State Street Global Advisors 2.91% · 12.95M sh
Swedbank Robur Fonder AB 2.30% · 10.26M sh
Baillie Gifford 2.06% · 9.15M sh
Geode Capital Management, LLC 1.92% · 8.55M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 25 buys · 25 sells

NameRoleStake
Mario Giuliani Former Director 4.80%
Pablo Legorreta Founder, Chairman of the Board & CEO 1.11%
Christopher Hite Chairman of Partnering & Investments 0.05%
Gregory Norden Independent Director 0.04%
Marshall Urist Head of Research & Investments 0.03%
Bonnie Bassler Independent Director 0.02%
Errol De Souza Former Independent Director 0.01%
Ted Love Lead Independent Director 0.01%
Catherine Engelbert Independent Director 0.01%
David Hodgson Independent Director 0.01%
Terrance Coyne Chief Financial Officer 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-05 Marshall Urist Head of Research & Investments Derivative Exercise and Retained +150,000 --
2026-11-05 Terrance Coyne Chief Financial Officer Other Acquisition +7,122 --
2026-11-05 Terrance Coyne Chief Financial Officer Derivative Exercise and Retained +250,000 --
2026-11-03 Christopher Hite Chairman of Partnering & Investments Other Acquisition +7,122 --
2026-11-03 Marshall Urist Head of Research & Investments Other Acquisition +5,341 --
2026-11-03 Pablo Legorreta Founder, Chairman of the Board & CEO Other Acquisition +42,209 --
2026-10-04 Marshall Urist Head of Research & Investments Automatic Disposition -4,126 $57.10
2026-09-29 Bonnie Bassler Independent Director Other Acquisition +642 $58.41
2026-09-27 Marshall Urist Head of Research & Investments Automatic Disposition -4,126 $57.88
2026-09-21 Christopher Hite Chairman of Partnering & Investments Automatic Disposition -100,000 $58.51–58.93
2026-08-18 Christopher Hite Chairman of Partnering & Investments Other Disposition -16,800 --
2026-08-17 Christopher Hite Chairman of Partnering & Investments Automatic Disposition -100,000 $59.97
2026-08-12 Terrance Coyne Chief Financial Officer Automatic Disposition -11,002 $58.59–59.14
2026-08-06 Marshall Urist Head of Research & Investments Other Derivative Disposition -3,000 --
2026-08-06 Terrance Coyne Chief Financial Officer Other Disposition -18,500 --
2026-08-06 Pablo Legorreta Founder, Chairman of the Board & CEO Other Derivative Disposition -30,000 --
2026-08-04 Christopher Hite Chairman of Partnering & Investments Other Acquisition +11,002 --
2026-08-04 Marshall Urist Head of Research & Investments Other Acquisition +8,252 --
2026-08-04 Terrance Coyne Chief Financial Officer Other Acquisition +11,002 --
2026-08-04 Pablo Legorreta Founder, Chairman of the Board & CEO Other Acquisition +65,216 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:28 · For reference only, not investment advice and not tailored to your situation.

Royalty Pharma discussion 0 comments

Add a comment